Bliss GVS Pharma appoints Mr. S.N. Kamath as Managing Director for three years

Promoter family joins the boardManagement Changes View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹175.01

prior close

₹176.60

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+1.4% vs market

Pharmaceuticals peers, median of 155sector+0.0%+1.5% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.9

15m

+0.6

30m

+2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.1+1.4+0.0+1.5

Next day

-0.0-0.5+0.5-0.2+0.2

-4.9-1.0-3.9-0.9-4.0

-6.8-1.8-5.0-1.5-5.3

-7.4-1.8-5.6-1.6-5.8

-6.6-0.4-6.1-1.0-5.6

-7.2+0.7-7.8+0.4-7.5

15d

-6.2-3.9-2.3-2.4-3.7

-7.7-9.4+1.7-7.9+0.3

+28.0-4.1+32.1-6.4+34.4

+10.9-16.1+26.9-14.4+25.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bliss GVS Pharma Board appointed Mr. S.N. Kamath, currently the CEO and promoter, as Managing Director for 3 years, subject to shareholder approval via Postal Ballot. Upon approval, he will serve as Managing Director and CEO. Mr. Kamath is the father of two existing Whole-Time Directors, Dr. Vibha Gagan Sharma and Mrs. Shruti Vishal Rao. The Board also approved the Postal Ballot Notice. Mr. Kamath has led the company's global expansion to over 60 countries.

Likely market impact

Promoter-led leadership continues. May strengthen strategic direction but further concentrates control within the promoter family already represented on the Board.